A Phase 1/2 interventional study of Using irrigation fluid with a certain concentration of norepinephrine in Urolithiasis and Lithotripsy, sponsored by Geriatric Hospital of Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Geriatric Hospital of Nanjing Medical University · Phase 1/2, Interventional, and Prevention
Urinary stone disease is globally prevalent with rising incidence and recurrence, imposing heavy socioeconomic burdens. Flexible ureteroscopy has advanced stone treatment. Single-use flexible ureteroscopes (su-fURS) combined with negative pressure ureteral access sheath (NPUAS), recommended by urology guidelines, improve surgical safety and stone-free rates and can treat stones ≤3 cm. However, su-fURS has poorer image quality, bleeding during lithotripsy may blur vision, frequently impairing efficiency and safety.
Norepinephrine (NE), a tyrosine-derived sympathomimetic amine, mainly activates α1 and β1 receptors. Doses above 3 μg/min trigger predominant α1-mediated vasoconstriction of arteries and veins. It can act on mucosal surfaces via irrigation fluid, making it favorable for initial hemostasis of injured mucosa. Firstly, this study aims to evaluate the efficacy and safety of low-concentration norepinephrine (NE) irrigation solution for hemostasis during lithotripsy performed with single-use flexible ureteroscope (su-fURS) combined with NPUAS, fifteen subjects will be enrolled in the study. Secondly, we explore the dose-effect relationships of four concentrations: 2 mg/3 L, 4 mg/3 L, 6 mg/3 L and 8 mg/3 L, and determine the optimal concentration by comprehensively evaluating hemostatic efficacy and safety. A total of 40 subjects will be enrolled, with 10 subjects in each concentration.
253 studies on the registry are indexed under Urolithiasis; 67 are open to participants now.
This study's planned enrollment of 55 is below the median of 100 across 182 interventional studies indexed under Urolithiasis.
Browse Urolithiasis studies →Geriatric Hospital of Nanjing Medical University is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
All enrolled participants receive lithotripsy with single-use flexible ureteroscope combined with negative pressure ureteral access sheath (NPUAS) for upper urinary tract calculi, standard normal saline irrigation fluid is used for flushing first, followed by treatment with irrigation fluid with a certain concentration of norepinephrine.
Drug: Using irrigation fluid with a certain concentration of norepinephrine
1. Treat with 4 mg/3 L norepinephrine (NE) irrigation fluid during su-fURS combined with NPUAS lithotripsy. 2. Treat with different concentrations of norepinephrine irrigation fluid (2 mg/3 L, 4 mg/3 L, 6 mg/3 L, 8 mg/3 L) when lithotripsy.
Hemoglobin concentration in irrigation fluid
Collect irrigation fluid samples before and after norepinephrine irrigation treatment, and measure the hemoglobin concentration in the irrigation fluid.
Time frame: Under identical operating conditions, the irrigation fluid was collected before and 3 minutes after treatment with 4 mg/3 L NE bitartrate irrigation fluid.
Systolic blood pressure (SBP)
After treatment with NE irrigation fluid. Systolic blood pressure was obtained from anesthesia records.
Time frame: Periprocedural
Mean arterial pressure (MAP)
After treatment with NE irrigation fluid. Mean arterial pressure (MAP) was obtained from anesthesia records
Time frame: Periprocedural
Heart rate (HR)
After treatment with NE irrigation fluid. Heart rate (HR) was obtained from anesthesia records.
Time frame: Periprocedural
Safety-related discontinuation proportion (SRD)
The proportion of participants whose study intervention is prematurely terminated because of safety-related adverse events or safety concerns.
Time frame: From initiation of study intervention up to completion of surgical procedure (within-operative period)
Concomitant medications(CMs)
Record the type, dosage, route, and duration of all concomitant medications administered to participants during the study, including medications for underlying diseases, peri-operative supportive drugs and rescue medications.
Time frame: From initiation of study intervention up to completion of surgical procedure (within-operative period)
Incidence of adverse events（IAEs）
Incidence of all-cause adverse events occurring in participants after study, including peri-operative complications and post-operative adverse events.
Time frame: From time of initial intervention through 8 hours post-procedure, assessed up to Post-operative Day 1
Stone clearance rate(SCR)
Proportion of participants achieving stone-free status, defined as no residual stones or residual stone fragments ≤2 mm on postoperative imaging examination.
Time frame: 1 day after surgical procedure
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Geriatric Hospital of Nanjing Medical University